Digital Therapeutics

Digital therapeutics (DTx) deliver evidence-based therapeutic interventions through software programs to treat, manage, or prevent diseases and disorders. Unlike wellness apps, DTx products undergo clinical trials and pursue regulatory authorization (FDA De Novo, CE marking) to demonstrate safety and efficacy comparable to pharmaceutical products. Pear Therapeutics, the first FDA-authorized DTx company (reSET for substance use disorder, Somryst for insomnia), filed for bankruptcy in 2023, creating a cautionary tale about the category's reimbursement challenges despite clinical validation. The fundamental challenge is the payer gap: health insurers have been slow to cover DTx products, and most DTx companies have struggled to generate revenue at scale despite FDA authorization. Companies that survived the correction (Akili, Freespira, Better Therapeutics) are pursuing more targeted commercial strategies focused on employer benefits, pharmaceutical partnerships, and specific disease states where the evidence and reimbursement case are strongest.